Inside Neko Health’s U.S. Invasion: Can Spotify Co-Founder’s Body-Scanning Venture Fix Preventative Medicine?

By Global Tech & Healthcare Desk
Expanded and Adapted from Original Reporting by Dominic-Madori Davis

Executive Overview

In an era defined by consumer-driven biohacking, algorithmic longevity tracking, and a systemic disillusionment with legacy healthcare, few startups have captured the global imagination quite like Neko Health. Co-founded by Spotify visionary Daniel Ek (frequently referenced in company milestones as David Ek) and entrepreneur Hjalmar Nilsonne, the Swedish preventative health company has quietly emerged as the most sought-after body scan operation in the world.

Combining high-resolution computer vision, advanced dermatological mapping, extensive blood panels, and metabolic monitoring, Neko Health operates on a provocative premise: healthcare should not be reactive, overly expensive, or inaccessible. Instead, it should look and feel as seamless as consumer technology.

Having originated in Sweden, Neko Health has raised nearly $1 billion in total funding—cementing its status as a heavyweight in the venture capital ecosystem. The company has officially touched down in New York City, sparking a massive domestic frenzy. According to corporate figures, Neko’s global waitlist has already topped 300,000 eager individuals.

Yet, as the company plants its flag in the United States, it enters a notoriously fractured medical landscape. American healthcare is plagued by prohibitive costs, administrative bloat, and a historical over-reliance on reactive, symptom-driven treatment rather than proactive wellness. To unpack the mechanics, potential, and skepticism surrounding the startup, TechCrunch sat down with Farooq Abbasi of Preface Ventures, an early backer of the company. Abbasi paints a picture of a venture that aims to transcend wellness fads, offering a glimpse into what the future of preventative medicine might look like if venture capital and cutting-edge artificial intelligence align.

Detailed Chronology: From Swedish Roots to the New York Launch

The trajectory of Neko Health reflects the rapid, hyper-scaled maturation common among top-tier European tech startups that successfully pivot to the American market.

• The Genesis in Stockholm: Co-founded by Daniel Ek and Hjalmar Nilsonne, Neko Health was born out of a shared frustration with traditional healthcare systems. The founders sought to apply modern engineering, artificial intelligence, and design principles to early disease detection. In its home country of Sweden, the concept quickly gained traction, proving that consumers were hungry for non-invasive, comprehensive health overviews.
• The Capital Surge: Fuelled by early successes and overwhelming consumer demand, Neko Health steadily accumulated financial backing. By mid-2026, the company achieved a monumental milestone, raising nearly $1 billion in total venture funding, anchored by prominent investors who see preventative care as the ultimate untapped market.
• The Global Waitlist Explosion: As word spread via tech circles, longevity podcasts, and word-of-mouth recommendations, Neko’s waitlist swelled internationally. Today, the global queue stands at over 300,000 people—a testament to the pent-up demand for rapid, comprehensive health diagnostics.
• The U.S. Landing in New York City: In a strategic move that marks its most significant geographical expansion to date, Neko Health has officially opened its doors in New York. The launch brings its signature one-hour scanning protocol out of Scandinavia and directly into the heart of the American financial and media capital, testing whether its sleek European model can scale within the complex regulatory and cultural ecosystem of the United States.

Supporting Context & Metrics: The Economics of Preventative Care

To understand why Neko Health is generating such intense fervor—and skepticism—one must examine the structural flaws of the U.S. medical system.

The American Preventative Care Deficit

In the United States, preventative care utilization remains stubbornly low. While public health campaigns continually emphasize the importance of early detection for conditions such as cardiovascular disease, metabolic syndrome, and skin cancers, millions of Americans skip routine checkups. The primary culprit? Cost and complexity.

Traditional healthcare in the U.S. is notoriously opaque. A battery of specialized screenings can result in a labyrinth of out-of-pocket expenses, insurance denials, and facility fees. Consequently, many individuals only seek medical intervention when symptoms become acute, dramatically lowering survival rates and driving up the total cost of care.

Neko’s Pricing and Financial Model

Neko Health seeks to disrupt this dynamic through transparent, streamlined pricing, though it remains a luxury out-of-pocket expense for many:

• The Scan Cost: Neko charges $500 for its comprehensive, one-hour preventative scan.
• Insurance Status: The service is not covered by traditional health insurance. However, the company notes that the fee should qualify as an eligible medical expense for individuals utilizing Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs).
• Biomarker Expansion: The diagnostic depth of the scan has evolved exponentially. Early beta testers, such as Preface Ventures’ Farooq Abbasi, have witnessed firsthand how rapidly the technology improves. “In my generation one scan, it was a blood test with 15 biomarkers,” Abbasi recalls. “It was fifty-five this time.”

Official Statements and Investor Perspectives

The integration of artificial intelligence and venture capital into healthcare frequently sparks debates regarding commercialization versus patient welfare. However, early investors like Farooq Abbasi argue that private capital is the exact catalyst needed to drag legacy medicine into the 21st century.

Bridging the Accessibility Gap

Abbasi is unapologetically bullish on Neko Health’s potential to democratize high-end diagnostics, viewing the current $500 price point as a stepping stone toward broader accessibility.

“I think preventative care and healthcare should be cheap and accessible,” Abbasi noted during his discussion with TechCrunch.

Having undergone the Neko scan twice, Abbasi speaks from personal experience. Unsurprisingly, his endorsement is glowing: “I think there should be Neko clinics everywhere.” He emphasizes that the value proposition lies not just in the volume of data collected, but in the clarity of the output.

Beyond the Wellness Fad

Critics of private body-scanning startups often lump them in with the broader, unregulated "wellness" industry—criticized for selling expensive peace of mind to the worried well while offering little clinical utility. Abbasi strongly rejects this characterization, arguing that Neko separates itself through rigorous technological application.

Powered by advanced computer vision and machine learning, Neko’s systems analyze skin lesions, body composition, and internal cardiovascular markers with a degree of consistency that human clinicians can struggle to maintain across long shifts.

“Neko Health isn’t just another wellness fad,” Abbasi argues, defining it as a tool that provides users with “actionable insights to make their lives better.”

By transforming raw data into clear, understandable lifestyle and medical directives, the company bridges the gap between raw diagnostics and actionable behavioral change.

Future Outlook: Scaling, Regulation, and the Road Ahead

Despite the palpable excitement surrounding the New York launch and the 300,000-strong waitlist, Neko Health faces a steep mountain to climb as it embeds deeper into the American market.

Regulatory and Scaling Hurdles

The U.S. healthcare market is heavily guarded by regulatory bodies, state-by-state medical board requirements, and stringent data privacy laws (such as HIPAA). Scaling a foreign-born health tech startup across multiple U.S. jurisdictions requires navigating a patchwork of compliance frameworks. Furthermore, scaling physical clinic infrastructure—ensuring that every location maintains the pristine, high-tech standard established in Stockholm—presents significant logistical challenges.

Venture Capital and Systemic Repair

Despite these hurdles, investors like Abbasi maintain an optimistic outlook. They believe that the infusion of venture capital into preventative health is part of a necessary paradigm shift. Rather than viewing the American healthcare system as a lost cause, Abbasi contends that private innovation can provide the shock therapy required to force legacy providers to adopt more proactive, tech-forward models.

If Neko Health can successfully clear regulatory hurdles, prove its long-term clinical efficacy, and gradually drive down costs, it may well fulfill its founders’ ambitions: transforming preventative medicine from an exclusive luxury into an everyday consumer standard.

Disclaimer: When you purchase through links in our articles, TechCrunch may earn a small commission. This does not affect our editorial independence.

About the Reporter

Dominic-Madori Davis is a senior venture capital and startup reporter at TechCrunch, based in New York City. You can contact or verify outreach via email at [email protected] or securely via Signal at +1 646 831-7565.